@article{oai:repo.qst.go.jp:00073840,
 author = {Nakakaji, Rina and Umemura, Masanari and Mitsudo, Kenji and Jeong-Hwan, Kim and Hoshino, Yujiro and Sato, Itaru and Masuda, Takatsugu and Yamamoto, Masahiro and Kioi, Mitomu and Koizumi, Toshiyuki and Fujita, Takayuki and Yokoyama, Utako and Iida, Masaki and Sato, Motohiko and Sato, Hiroshi and Murofushi, Shoko and Shibata, Sayaka and Aoki, Ichio and Eguchi, Haruki and Tohnai, Iwai and Ishikawa, Yoshihiro and Nakakaji, Rina and Umemura, Masanari and Sato, Itaru and Sato, Hiroshi and Shibata, Sayaka and Aoki, Ichio},
 issue = {21},
 journal = {Oncotarget},
 month = {Feb},
 note = {(Fe(Salen)) is an anti-cancer agent with intrinsic magnetic property. Here, we covalently linked Fe(Salen) to paclitaxel (PTX), a widely used anti-cancer drug, to obtain a magnetized paclitaxel conjugate (M-PTX), which exhibited magnetic characteristics for magnet-guided drug delivery and MRI visualization. M-PTX increased apoptosis and G2/M arrest of cultured human oral cancer cell lines in the same manner as PTX. Furthermore, marked contrast intensity was obtained in magnetic resonance imaging (MRI) of M-PTX. In a mouse oral cancer model, a permanent magnet placed on the body surface adjacent to the tumor resulted in distinct accumulation of M-PTX, and the anti-cancer effect was greater than that of M-PTX without the magnet. We believe that this strategy may improve future cancer chemotherapy by providing conventional anti-cancer drugs with novel functionalities such as magnet-guided drug delivery or MRI-based visualization/quantitation of drug distribution.},
 pages = {15591--15605},
 title = {Treatment of oral cancer using magnetized paclitaxel.},
 volume = {9},
 year = {2019}
}